转移性结直肠癌的三线治疗及以上。
Metastatic colorectal cancer- third line therapy and beyond.
机构信息
Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA, Australia.
Department of Medical Oncology, FCIC and Flinders University, Bedford Park, SA, Australia.
出版信息
Expert Rev Anticancer Ther. 2024 May;24(5):219-227. doi: 10.1080/14737140.2024.2334784. Epub 2024 Apr 3.
INTRODUCTION
The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.
METHOD
In this narrative review, we provide a comprehensive summary of data from key clinical trials and discuss how to integrate these agents into the current treatment landscape of metastatic colorectal cancer.
EXPERT OPINION
In the era of precision medicine, molecular testing plays an increasingly important role in the management of mCRC. Efforts need to be made to target treatment based on molecular test results.
简介
在过去的几十年中，转移性结直肠癌（mCRC）患者的治疗效果显著提高。转移性结直肠癌是一种高度异质性的癌症。除二线化疗外，治疗决策通常基于分子检测。
方法
在这篇综述中，我们提供了关键临床试验数据的全面总结，并讨论了如何将这些药物整合到转移性结直肠癌的当前治疗领域中。
专家意见
在精准医学时代，分子检测在 mCRC 的治疗管理中发挥着越来越重要的作用。需要努力根据分子检测结果靶向治疗。
Zotero 插件